[go: up one dir, main page]

MX2017003262A - Composiciones y métodos para el tratamiento de lesiones cutáneas precancerosas. - Google Patents

Composiciones y métodos para el tratamiento de lesiones cutáneas precancerosas.

Info

Publication number
MX2017003262A
MX2017003262A MX2017003262A MX2017003262A MX2017003262A MX 2017003262 A MX2017003262 A MX 2017003262A MX 2017003262 A MX2017003262 A MX 2017003262A MX 2017003262 A MX2017003262 A MX 2017003262A MX 2017003262 A MX2017003262 A MX 2017003262A
Authority
MX
Mexico
Prior art keywords
compositions
treatment
methods
skin lesions
cancerous skin
Prior art date
Application number
MX2017003262A
Other languages
English (en)
Other versions
MX387661B (es
Inventor
DEMEHRI Shadmehr
Cornelius Lynn
Kopan Raphael
Original Assignee
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington filed Critical Univ Washington
Publication of MX2017003262A publication Critical patent/MX2017003262A/es
Publication of MX387661B publication Critical patent/MX387661B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/04—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente descripción comprende composiciones y métodos para el tratamiento de lesiones cutáneas precancerosas. Las composiciones de la invención comprenden un agente citotóxico y un inductor de linfopoyetina estromal tímica (TSLP).
MX2017003262A 2014-09-10 2015-09-10 Composiciones y métodos para el tratamiento de lesiones cutáneas precancerosas. MX387661B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462048586P 2014-09-10 2014-09-10
PCT/US2015/049434 WO2016040638A2 (en) 2014-09-10 2015-09-10 Compositions and methods for treatment of pre-cancerous skin lesions

Publications (2)

Publication Number Publication Date
MX2017003262A true MX2017003262A (es) 2017-12-04
MX387661B MX387661B (es) 2025-03-18

Family

ID=55459695

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017003262A MX387661B (es) 2014-09-10 2015-09-10 Composiciones y métodos para el tratamiento de lesiones cutáneas precancerosas.

Country Status (16)

Country Link
US (3) US10905763B2 (es)
EP (2) EP3939593A1 (es)
KR (1) KR102573972B1 (es)
CN (1) CN107073017A (es)
AU (3) AU2015315047A1 (es)
BR (1) BR112017004893A2 (es)
CA (1) CA2963922C (es)
CL (1) CL2017000605A1 (es)
DK (1) DK3191103T3 (es)
EA (1) EA036833B1 (es)
ES (1) ES2891305T3 (es)
IL (1) IL251089A0 (es)
MX (1) MX387661B (es)
PH (1) PH12017500677A1 (es)
UA (1) UA121222C2 (es)
WO (1) WO2016040638A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3939593A1 (en) 2014-09-10 2022-01-19 Washington University Compositions and methods for treatment of pre-cancerous skin lesions
HRP20210323T1 (hr) * 2017-02-06 2021-05-14 3Skin As Pripravak za zaštitu od sunca
JP7387617B2 (ja) * 2017-11-09 2023-11-28 デイヴィッド グレイザー スコット 皮膚病変の治療用の組成物および方法
US20210177831A1 (en) * 2018-07-05 2021-06-17 The General Hospital Corporation Compositions and methods for local delivery of pharmaceutical agents to treat cancer
CA3140952A1 (en) * 2019-05-17 2020-11-26 The Trustees Of The University Of Pennsylvania Methods and compositions for treating obesity and/or skin disorders
KR102321027B1 (ko) 2019-06-14 2021-11-03 이준성 전선관 커넥터
KR102316303B1 (ko) 2019-06-17 2021-10-22 이준성 전선 연결용 커버판
WO2021099901A1 (en) * 2019-11-19 2021-05-27 Intas Pharmaceuticals Ltd. Stable topical pharmaceutical composition
US12440537B1 (en) * 2020-10-13 2025-10-14 Washington University Compositions and methods for treating skin diseases, disorders, or conditions
DK202370132A1 (en) * 2023-03-14 2024-10-10 Repoceuticals Aps Compositions for use in the treatment of actinic keratosis

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4394448A (en) 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4529561A (en) 1978-03-24 1985-07-16 The Regents Of The University Of California Method for producing liposomes in selected size range
US4241046A (en) 1978-11-30 1980-12-23 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4925661A (en) 1984-04-19 1990-05-15 Leaf Huang Target-specific cytotoxic liposomes
US4957735A (en) 1984-06-12 1990-09-18 The University Of Tennessee Research Corporation Target-sensitive immunoliposomes- preparation and characterization
US4755388A (en) 1984-11-09 1988-07-05 The Regents Of The University Of California Liposome-encapsulated 5-fluoropyrimidines and methods for their use
DE3542773A1 (de) 1985-12-04 1987-06-11 Roehm Pharma Gmbh Hautwirksame pharmaka mit liposomen als wirkstofftraeger
US4828837A (en) 1987-03-30 1989-05-09 Liposome Technology, Inc. Non-crystalline minoxidil composition, its production and application
US4820711A (en) * 1987-05-15 1989-04-11 Pearlman Dale L Method for treating actinic keratosis with cytotoxic agents
US5077211A (en) 1988-07-06 1991-12-31 Applied Genetics, Inc. Purification and administration of dna repair enzymes
US5043164A (en) 1989-01-17 1991-08-27 The University Of Tennessee Research Corporation Blood-stable, cholesterol-free liposomes
US5064655A (en) 1989-02-24 1991-11-12 Liposome Technology, Inc. Liposome gel composition and method
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
AU4717399A (en) * 1998-06-26 2000-01-17 Dermik Laboratories Inc. Method of treatment for dermatological disorders and compositions therefor
US20010002396A1 (en) * 1998-07-16 2001-05-31 Charles Achkar Compositions and methods of treating skin conditions
US20090098065A1 (en) * 2000-01-11 2009-04-16 Avikam Harel Composition and methods for the treatment of skin disorders
EP1491188A1 (en) * 2003-06-25 2004-12-29 G2M Cancer Drugs AG Topical use of valproic acid for the prevention or treatment of skin disorders
US20050079235A1 (en) * 2003-10-09 2005-04-14 Eggert Stockfleth Use of a polyphenol for the treatment of actinic keratosis
EP1692486B1 (en) 2003-12-12 2015-10-28 Saint Louis University Biosensors for detecting macromolecules and other analytes
EP1737453A4 (en) 2004-03-22 2008-11-26 Celgene Corp METHOD FOR THE USE OF IMMUNOMODULATORY COMPOUNDS AND COMPOSITIONS CONTAINING THEREOF FOR THE TREATMENT AND SUPPLY OF SKIN DISEASES OR DISORDERS
US9173835B2 (en) * 2005-05-10 2015-11-03 Dermipsor Ltd. Compositions and methods for treating hyperproliferative epidermal diseases
GEP20146198B (en) * 2008-12-19 2014-11-25 Graceway Pharmaceuticals Llc Lower dosage strength imiquimod formulations and short dosing regimens for treating actinic keratosis
WO2012074842A2 (en) * 2010-11-23 2012-06-07 The United States Of America, As Represented By The Secretary, National Institute Of Health Compositions and methods for treating neoplasia
DE102010062474A1 (de) 2010-12-06 2012-06-06 Robert Bosch Gmbh Maschinen-Steuerverfahren und -vorrichtung
WO2012176212A1 (en) * 2011-06-20 2012-12-27 V.B. Medicare Pvt. Ltd. Carrier based nanogel formulation for skin targeting.
EP3939593A1 (en) 2014-09-10 2022-01-19 Washington University Compositions and methods for treatment of pre-cancerous skin lesions

Also Published As

Publication number Publication date
BR112017004893A2 (pt) 2017-12-12
CA2963922A1 (en) 2016-03-17
AU2020281015B2 (en) 2022-10-06
MX387661B (es) 2025-03-18
PH12017500677A1 (en) 2017-10-09
US20230026855A1 (en) 2023-01-26
EP3191103A4 (en) 2018-05-16
AU2020281015A1 (en) 2021-01-07
US10905763B2 (en) 2021-02-02
EP3939593A1 (en) 2022-01-19
US20210128732A1 (en) 2021-05-06
AU2023200052A1 (en) 2023-02-09
DK3191103T3 (da) 2021-09-27
CA2963922C (en) 2023-06-27
EP3191103B1 (en) 2021-09-01
CN107073017A (zh) 2017-08-18
WO2016040638A2 (en) 2016-03-17
CL2017000605A1 (es) 2017-11-10
KR20170058961A (ko) 2017-05-29
US11478549B2 (en) 2022-10-25
IL251089A0 (en) 2017-04-30
UA121222C2 (uk) 2020-04-27
AU2015315047A1 (en) 2017-04-27
WO2016040638A3 (en) 2016-09-01
EP3191103A2 (en) 2017-07-19
US20170246299A1 (en) 2017-08-31
KR102573972B1 (ko) 2023-09-01
US12186394B2 (en) 2025-01-07
ES2891305T3 (es) 2022-01-27
AU2020281015C1 (en) 2023-01-19
EA201790565A1 (ru) 2017-08-31
EA036833B1 (ru) 2020-12-24

Similar Documents

Publication Publication Date Title
MX2017003262A (es) Composiciones y métodos para el tratamiento de lesiones cutáneas precancerosas.
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
MX2017006283A (es) Peptidos macrociclicos utiles como inmunomoduladores.
EA201691582A1 (ru) Новые фармацевтические препараты
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
BR112016026378A2 (pt) formulações e métodos para tratamento com queratina
MX385845B (es) Usos y composiciones de la flagelina
MX2016014247A (es) Conjugados de anticuerpo-farmaco anti-proteina tirosina quinasa 7 (anti-ptk7).
PE20180243A1 (es) Composiciones que comprenden cepas bacterianas
MX2017004473A (es) Formulaciones de betalactamasa y usos de las mismas.
LT3200815T (lt) Būdai ir kompozicijos, skirti vėžio gydymui
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
IL240022A0 (en) Titanium nitride hard mask and etch residue removal
MX2017005975A (es) Anticuerpos anti factor de crecimiento derivado de plaquetas b (pdgf-b) y metodos de uso.
MX2017008097A (es) Sintesis comercialmente viable de cantaridina y derivados bioactivos de cantaridina.
MX2017006019A (es) Apilimod para uso en el tratamiento de melanoma.
ZA201703467B (en) Methods of treating ocular conditions
MX2017007000A (es) Composiciones que comprenden acido 15-hidroxieicosapentaenoico (15-hepe) y metodos para tratar o prevenir la fibrosis usando las mismas.
MX2016008150A (es) Formulaciones de berberina y usos de las mismas.
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
FR3019746B1 (fr) Diffuseur de substances, notamment de parfum, d'huiles essentielles
DE112015002229A5 (de) Formulierungen zur Behandlung von Hyperthyreose
PH12016501434A1 (en) Compositions for use in the treatment of allergic conditions
LT3154542T (lt) Būdai ir kompozicijos, skirti gydyti prislėgtą nuotaiką
MX383460B (es) Derivados peptidicos novedosos y sus usos.